What NexoBrid Treats: Main Uses and Benefits

НексоБрид is applied in clinical settings that involve the acute phase of deep partial-thickness and full-thickness thermal burns. It is relevant for managing the presence of eschar, the non-viable dead tissue layer, and is commonly used to help with the required removal of this hardened tissue from wounds in both adults and pediatric patients.

The treatment is relevant for easing the overall symptom load by supporting the selective removal of the non-viable tissue while supporting the preservation of underlying dermal tissue that is considered salvageable. This selective process may contribute to the potential for the patient’s own skin to heal, where appropriate.

The medication is considered relevant in conditions where the severity of tissue damage often involves the need for surgical debridement. By achieving debridement, the treatment may assist with reducing the need for or extent of subsequent surgical procedures and autografting. The treatment provides supportive relief for the patient and contributes to easing the overall symptomatic burden of acute injury management.

“The selective nature of the treatment may assist with maintaining a sense of stability when symptoms are more noticeable during phases of heightened symptoms.”

Quick Fact: Relief for Deep Thermal Injuries
Symptom Addressed: Non-viable tissue (eschar)
Conditions: Deep partial-thickness and full-thickness burns
Primary Benefit: Supports viable tissue preservation
Clinical Scenario: Early, acute symptom management

Regulatory References

1. European Medicines Agency (EMA) overview

Official Regulatory Eligibility and Restrictions

NexoBrid (anacaulase-bcdb) is indicated for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Eligibility for use is strictly defined by regulatory documents based on patient characteristics and burn type.

Classification	Population or Condition	Status
Absolute Contraindication	Known hypersensitivity to anacaulase-bcdb, bromelain, pineapples, or papayas/papain.	Must NOT be used
Coagulation Status	Patients with uncontrolled disorders of coagulation.	Avoid use
Special Caution	Patients on anticoagulant therapy or with low platelet counts.	Use with caution
Age Restriction	Subjects 65 years and older.	Insufficient data in studies
Pregnancy/Lactation	Pregnant or breastfeeding women.	Manufacturer makes no recommendation due to lack of data

Limitations of Use (Safety/Effectiveness Not Established)

Safety and effectiveness have not been established for treatment of several specific conditions, thereby restricting use in these areas. These include chemical or electrical burns, and burns on the face, perineum, or genitalia. Restrictions also apply to circumferential burns and burns on the feet of patients with diabetes mellitus or occlusive vascular disease, or in patients with significant cardiopulmonary disease.

Interactions with other medicines and products

Official Regulatory Interaction Profile

The officially documented interaction profile for НексоБрид (anacaulase-bcdb) is narrowly defined, primarily focusing on potential pharmacodynamic interactions related to the blood coagulation system. The regulatory basis for this profile is restricted, as no dedicated clinical drug interaction studies were conducted for the product to assess changes in systemic drug levels.

Documented Interaction Categories

Category	Official Interaction Data
Pharmacodynamic Risk	Co-administration with anticoagulant therapy and other medicinal products affecting coagulation (e.g., antiplatelets, fibrinolytics) may be associated with an increased risk of bleeding. The active ingredient may contribute to reduced platelet aggregation or increased prothrombin time.
Herbal/Supplement Interaction	Caution is noted regarding concurrent use with herbal products or supplements known to affect blood coagulation, as this may reinforce the documented pharmacodynamic risk.
PK/Metabolic Interactions	None documented. The official label states that no clinical studies were performed to establish interactions involving CYP enzymes or PK alterations.

Interaction-Related Constraints

Interaction-related restrictions center on the coagulation system. The potential for adverse interaction is officially recognized as being heightened in patients with pre-existing conditions that increase the risk of bleeding, such as low platelet counts. The regulatory documents do not specify mandatory timing separation rules for co-administration with other medicines.

Selective Proteolytic Cleavage of Eschar Proteins

This core domain outlines the molecular mechanism where the active component, anacaulase-bcdb, utilizes thiol endopeptidase activity to directly hydrolyze peptide bonds within the non-viable protein matrix of the eschar. This targeted chemical breakdown results in the hydrolysis of denatured collagen and fibrin, the protein scaffolding of the eschar.

---

️ Differential Substrate Recognition for Dermal Sparing

The mechanism is defined by differential substrate recognition, which is the enzyme's kinetic preference for cleaving the disorganized denatured proteins of the eschar compared to the native, structurally intact proteins found in the underlying viable dermis. This mechanistic selectivity limits the physical breakdown to the non-viable tissue, producing the functional consequence of sparing the structure of viable skin and microvasculature.

---

️ Cooperative Action for Complete Tissue Disintegration

Efficacy is achieved through the cooperative action of the concentrated mixture of proteolytic enzymes, where the combined activity contributes to the necessary "escharase" power. This collective mechanism involves the simultaneous breakdown of multiple protein components, resulting in the detachment of the eschar from the underlying tissue.

How НексоБрид is Used: Official Administration Guidelines

NexoBrid is an enzymatic debriding agent strictly designated for topical use (cutaneous application) and must be administered by trained healthcare professionals only in specialist burn centers. The entire treatment is structured as a time-bound, procedural course.

---

Administration Scope

Feature	Instruction
Route of administration	Topical use (cutaneous application) only.
Dosing schedule (Adults)	A 3 mm thick layer applied to a burn area up to 15% of the Total Body Surface Area (TBSA) for the first application. Total treated area across all applications must not exceed 20% TBSA.
Preparation requirements	The lyophilized powder and gel vehicle must be mixed immediately prior to use at the patient's bedside and applied within 15 minutes of mixing.
Special procedural conditions	The product must remain on the burn wound for exactly 4 hours. The wound must be cleaned and kept moist prior to application, and the surrounding healthy skin protected with a barrier.

---

Age-Group Administration Rules

Administration rules differ based on age, primarily concerning the maximum area treated and the allowance for a second application:

• Adults: Up to two applications are permitted, separated by 24 hours, provided the total treated area limit of 20% TBSA is not exceeded.
• Pediatric Patients (6 to 17 years): Maximum single application of 15% TBSA. A second application is not recommended.
• Pediatric Patients (0 to < 6 years): Maximum single application of 10% TBSA. A second application is not recommended.

---

Resulting Procedural Structure

The treatment requires the wound to be cleaned, the area moistened, and the mixture applied within 15 minutes. After the mandatory 4-hour contact time, the product is removed and the treated area wiped clean. This standardized procedure defines the maximum area and duration for which the medicine can be used to maintain the established clinical framework.

НексоБрид: Recent Clinical Evidence

Clinical trials, including the pivotal DETECT study and subsequent pediatric studies, have evaluated НексоБрид (anacaulase-bcdb) for the removal of eschar (dead tissue) in patients with deep partial thickness (DPT) and/or full thickness (FT) thermal burns.

---

Efficacy and Procedure Comparison

Randomized controlled trials have compared the use of НексоБрид to the Standard of Care (SOC) for eschar removal, which often involves surgical excision. The primary efficacy findings have focused on the incidence and speed of complete eschar removal and the resulting need for surgery:

Efficacy Endpoint	НексоБрид Arm	Standard of Care (SOC) Arm
Incidence of Eschar Removal (≥95%)	High percentage reported in studies	Varies by surgical method used
Median Time to Removal	Significantly shorter (e.g., 1 day)	Significantly longer (e.g., 6 days)
Incidence of Excision/Autografting	Lower incidence of surgical excision and subsequent autografting required for DPT wounds

Studies in both adult and pediatric patients suggest that enzymatic debridement with НексоБрид may allow for earlier, complete removal of eschar, potentially preserving viable dermal tissue and reducing the need for traditional surgical excision and associated blood loss.

---

Safety and Long-Term Outcomes

The safety profile was assessed in these trials. The most commonly reported adverse reactions in adult patients included pruritus (itching) and pyrexia (fever). Serious hypersensitivity reactions, including anaphylaxis, have been reported in postmarketing use, highlighting the need to check for known allergies to bromelain, papain, or pineapples.

Follow-up assessments using scales like the Modified Vancouver Scar Scale (MVSS) have been conducted to evaluate long-term scar quality and function. Results from comparative trials have supported the non-inferiority of НексоБрид compared to SOC in long-term cosmesis and function of the resulting burn scars at 12 and 24 months post-wound closure.

Common questions about НексоБрид (FAQ)

Q: How does НексоБрид differ from similar medications that treat the same condition?

Official documents describe the drug as an enzymatic debriding agent that uses differential substrate recognition. This means the drug is indicated to selectively break down non-viable, damaged eschar tissue while sparing the structure of underlying viable tissue, which defines its unique action compared to traditional methods.

Q: Does НексоБрид interact with common dietary supplements like vitamins or minerals?

Regulatory documents advise caution regarding co-administration with supplements known to affect blood coagulation (blood clotting), as there is a potential pharmacodynamic risk. The official product information does not document specific interactions with general common vitamins or minerals.

Q: What is the process by which НексоБрид is broken down in the body (metabolism)?

The official labeling states that no dedicated clinical studies were performed to assess the drug's systemic changes or its metabolic profile, known as pharmacokinetics ( PK). This means the systemic metabolic fate is not documented in the product information.

Q: What physical signs are associated with a potential severe allergic reaction to НексоБрид?

Safety information includes warnings about the potential for serious hypersensitivity reactions, such as anaphylaxis. Signs associated with these reactions, as described in safety materials, may involve difficulty breathing, the development of hives, swelling of the face, throat, or tongue, or a rapid drop in blood pressure.

Q: Does НексоБрид interact with common herbal remedies such as St. John's Wort?

Caution is noted in official documents regarding the concurrent use of herbal products or supplements that are specifically known to affect blood coagulation (clotting). The documented interaction risk primarily relates to substances that interfere with the coagulation system.

Q: Is it considered safe to use НексоБрид with over-the-counter pain relievers like ibuprofen or acetaminophen?

Official labeling advises caution when using the drug concurrently with medicines that affect coagulation, such as those that affect coagulation (e.g., certain NSAIDs). However, no specific caution is noted for common non-NSAID pain relievers, such as acetaminophen, that do not affect the blood clotting process.

Q: Does regulatory information indicate that НексоБрид can cause weight changes?

The official adverse reactions tables classify effects based on reported incidence in clinical trials. Weight change (gain or loss) is not among the most commonly reported adverse reactions listed in the official tables.

Q: Is it necessary to avoid alcohol entirely while using НексоБрид?

Official regulatory documents do not include a specific warning or necessity to avoid alcohol while undergoing treatment with the drug.

Q: Is there a described risk of becoming physically dependent on НексоБрид?

The drug is an enzymatic debriding agent for topical use. Given the nature of this topical enzymatic agent, the official labeling contains no warnings regarding a risk of physical dependence or abuse.

Q: Is it a common experience to feel drowsy or fatigued when first starting НексоБрид?

Adverse effects are categorized by frequency based on clinical trials. Official safety information does not list drowsiness or fatigue among the most common adverse reactions reported by patients.

Q: Are there known interactions between НексоБрид and common birth control methods?

Official labeling is focused on interactions that affect systemic drug levels or the coagulation system. The documents do not contain any specific warnings or data concerning an interaction between the drug and common hormonal birth control methods.

Q: What general instructions are provided about managing a missed dose of НексоБрид?

Because this treatment is a time-bound, procedural course administered by a healthcare professional in a specialized setting, the concept of a 'missed dose' for self-administration is not applicable.

Q: Are there any specific foods or beverages that are described as interacting with НексоБрид?

Official regulatory documents describe drug-drug interactions but do not list any known interaction with specific foods or beverages that must be avoided during treatment.

Q: Does the product information include warnings about driving or operating machinery while using НексоБрид?

Official product information does not include a specific warning advising patients against driving or operating machinery due to the direct effects of the medicine itself.

Q: Are there documented reports of НексоБрид affecting blood pressure or heart rate?

Official adverse reaction data from clinical trials report that hypotension (low blood pressure) and tachycardia (fast heart rate) occurred with a common incidence (1% to 10% of patients in studies). These effects are classified based on their reported frequency.

Q: Can individuals with mild or moderate kidney impairment use НексоБрид?

Due to the topical administration and lack of documented systemic absorption or metabolic concerns, renal (kidney) impairment is not listed in the official contraindications or warnings.

Q: Does the FDA or similar agency require a 'black box' warning for НексоБрид?

The FDA Prescribing Information does not contain the specific Boxed Warning (Black Box) structure, which is reserved for the most serious warnings. However, the official documentation does include serious warnings regarding hypersensitivity and coagulopathy in the main 'Warnings and Precautions' section.

Q: Does the prescribing information discuss the general practice of suddenly discontinuing НексоБрид?

Since the drug is administered as a single, time-bound procedural treatment for acute wound care, the concept of suddenly discontinuing the medicine is not relevant and is not discussed in the prescribing information.

Q: Does the effectiveness of НексоБрид decrease or lessen over a long period of time?

The drug is used for the acute task of eschar removal in a single procedure. Long-term studies were conducted to assess the quality of the resulting burn scar, and these findings supported that the long-term outcome was comparable to the standard of care over a period of up to 24 months.

How to Store and Dispose of NexoBrid

NexoBrid (anacaulase-bcdb) must be handled and stored under strict conditions to preserve the activity of its enzymatic components.

---

Official Storage Requirements

Condition	Requirement
Temperature	Store refrigerated at mathbf2^circC to mathbf8^circC (36^circF to 46^circF). Do not freeze.
Protection	Keep in the original carton to protect the product from light. Store the package upright.
Shelf-Life	The unmixed product maintains stability for 36 months when refrigerated.

---

Post-Preparation and Disposal

The mixed product (powder and gel) is only stable for a short period and must be used within 15 minutes of preparation. Any product not used within this window must be discarded. NexoBrid is for single use only. Unused portions and waste materials must be disposed of in accordance with local regulatory requirements for pharmaceutical waste.